The first CAR-T treatment to win approval from the Food and Drug Administration racked up just $12 million in sales last quarter, a reminder that the therapy has a long way to go if it’s ever going to meet Wall Street’s blockbuster expectations.

Analysts expect Novartis’ Kymriah, which costs $475,000 for a one-time dose, to bring in about $159 million this year, according to Evaluate Pharma, meaning the drug maker is going to need to pick up the commercial pace if it hopes to avoid disappointment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Follow the money,until Medicare and insurers cover the full cost of these treatments,including in hospital costs a slow ramp up was expected.I am sure this will accelerate soon

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy